Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28216931 | 0.89 | ALDH1A1 (0.57) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL671495 | 0.77 | DAO (0.65) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL24103159 | 0.76 | DAO (0.50) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1176828 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL2595303 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL30678374 | 0.75 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL27680363 | 0.75 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL27984199 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL7639694 | 0.75 | RIPK1 (0.59) | DAORIPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107298679-B | A kind of synthetic method of chloro- 1H- pyrrolo- [2,3-B] pyridine -4- amine of 5- | 上海吉尔多肽有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-108997343-A | A kind of preparation method of pharmaceutical composition that treating febrile convulsion | 丁敏 | 2018-12-14 | — | — | CN | claimed |
| CN-108794472-A | A kind of preparation method of the chloro- 7- azaindoles of 4- | 南通雅本化学有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-108101903-A | A kind of synthetic method of the chloro- 7- azaindoles of 5- | 东莞市联洲知识产权运营管理有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-108079938-A | There is the PERFORMANCE OF MODIFIED VERMICULITE adsorbent of absorption property to the orthophosphates in water body | 北京益清源环保科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-107513061-A | A kind of preparation method of disubstituted 7 7-azaindole derivatives | 湖南华腾制药有限公司 | 2017-12-26 | — | — | CN | claimed |
| CN-107298680-A | Production process of 4-chloro-7-azaindole | 海门华祥医药科技有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-107298679-A | A kind of synthetic method of the amine of 5 chlorine 1H pyrrolo-es [2,3 B] pyridine 4 | 上海吉尔多肽有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-107235976-A | Synthetic method of 3-chloro-7-azaindole | 海门华祥医药科技有限公司 | 2017-10-10 | — | — | CN | claimed |
| CN-104231141-B | A kind of amino nitrogen heterocyclic ring resin and preparation method thereof | 西安蓝晓科技新材料股份有限公司 | 2017-03-29 | — | — | CN | claimed |
| CN-106279156-A | A kind of synthetic method of 5 chlorine 7 azaindoles | 叶芳 | 2017-01-04 | — | — | CN | claimed |
| CN-105777747-A | 4-chloro-7-azaindole and preparation method thereof | 叶芳 | 2016-07-20 | — | — | CN | claimed |
| CN-105669677-A | Synthetic method of 6-chloro-7-azaindole | 苏州艾缇克药物化学有限公司 | 2016-06-15 | — | — | CN | claimed |
| CN-104478909-A | Synthetic process of heterocyclic boric acid compound | SHANGHAI TITAN TECHNOLOGY CO LTD | 2015-04-01 | — | — | CN | claimed |
| CN-104231141-A | Amino nitrogen heterocyclic ring resin and preparation method thereof | XI AN SUNRESIN NEW MATERIALS CO LTD | 2014-12-24 | — | — | CN | claimed |
| CN-117098763-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4274832-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | DAO 903/4885RIPK1 4799/4885CCNB2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.